DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for bone benign neoplasm — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBone benign neoplasm maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for bone benign neoplasm is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
COMM domain containing 10 (COMMD10) — COMMD10 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8P0W · 2.9 Å · ligand none (apo structure). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Surgical Oncology · 2022 · 12 citations · open access
Fifty years of bone tumors
AbstractThere have been enormous advances in the treatment of bone tumors over the past half-century. The most notable of these has been the transition from amputation as the standard of care to limb salvage surgery. This transition is the result of advances in imaging techniques, accurate diagnosis, systemic therapies (including chemotherapy), and prosthetic design for the reconstruction of musculoskeletal defects. Advances have also been made in the management of benign and metastatic bone tumors.
Journal of Bone and Joint Surgery - British Volume · 1950 · 0 citations
NEOPLASMS OF BONE AND RELATED CONDITIONS; Their Etiology, Pathogenesis, Diagnosis and Treatment. By Bradley L. Coley, M.D., Attending Surgeon, Bone Tumor Department, Memorial Hospital for Cancer and Allied Diseases; Assistant Professor of Clinical Surgery, Cornell. 10x7 in. Pp. xiv+765, with 389 figures and 53 tables. Index. 1949. New York: Paul B. Hoeber, Inc. London: Cassell & Co. Ltd. Price £6, l0s
AbstractNEOPLASMS OF BONE AND RELATED CONDITIONS; Their Etiology, Pathogenesis, Diagnosis and Treatment. By Bradley L. Coley, M.D., Attending Surgeon, Bone Tumor Department, Memorial Hospital for Cancer and Allied Diseases; Assistant Professor of Clinical Surgery, Cornell. 10x7 in. Pp. xiv+765, with 389 figures and 53 tables. Index. 1949. New York: Paul B. Hoeber, Inc. London: Cassell & Co. Ltd. Price £6, l0s
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
